Monday , August 21 2017
Home / News / Hormonal maintenance therapy can improve survival in women with rare ovarian, says study

Hormonal maintenance therapy can improve survival in women with rare ovarian, says study

Washington: Women with a rare type of epithelial ovarian or peritoneum cancer, can now take sigh of relief.

A new study reveals that, hormonal maintenance therapy (HMT) may significantly improve survival in women having low-grade serous carcinoma (LGSC).

The research was published in the Journal of Clinical Oncology.

According to the researchers, LGSC accounts for 10 percent of serous carcinomas of the ovary/peritoneum. It is diagnosed in women, who are in their early 40s and 50s (however, teenagers and women in their 20s and 30s also may be diagnosed).

“MD Anderson has a long history of discovery in this field of rare ovarian cancer — publishing a study in 2004 that changed the way serous carcinomas were graded and thereby identifying LGSC. MD Anderson research also showed that LGSC is relatively chemo-resistant compared with high-grade serous carcinoma,” said David M. Gershenson, M.D., professor, Gynecologic Oncology and Reproductive Medicine.

These findings could one day represent a significant improvement to frontline standard of care.

“There is a true unmet need for these patients — roughly 70 percent of women with this disease will experience a recurrence of the cancer at some point. Our group published research demonstrating that hormonal therapy showed promise in the recurrent setting, with most patients responding or having stable disease. It was a natural progression over time that we began to study this up front, after women received their primary chemotherapy,” Gershenson shared.

The study analyzed data from 203 women with stage II-IV LGSC treated at MD Anderson between 1981 and 2013 to evaluate the effect of HMT, compared with surveillance, after surgery and chemotherapy.

Women who received HMT (70 patients) showed an average progression-free survival (PFS) of 64.9 months compared with 26.4 months for those in the surveillance group (133 patients). Overall survival (OS) was 115.7 months following HMT, versus 102.7 months for the surveillance group.

“Hormonal therapy has shown promising results in reducing cancer recurrence, and there is increasing interest in integrating this approach into first-line therapy. If confirmatory research in a clinical trial setting shows hormonal maintenance therapy can prevent or delay recurrence of this cancer subtype, it would be practice changing,” said Gershenson.

Though recruitment for this patient population is challenging given the rarity of the disease, Gershenson noted that a prospective international Phase three clinical trial has been designed. (ANI)